Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients
- PMID: 37335862
- DOI: 10.1093/ajhp/zxad137
Comparison of effectiveness and safety of sodium polystyrene sulfonate and sodium zirconium cyclosilicate for treatment of hyperkalemia in hospitalized patients
Abstract
Purpose: Potassium binders are frequently utilized for the treatment of hyperkalemia in hospitalized patients; however, there is limited data directly comparing individual agents. The purpose of this study was to compare the effectiveness and safety of sodium polystyrene sulfonate (SPS) and sodium zirconium cyclosilicate (SZC) for hyperkalemia treatment in hospitalized patients.
Methods: This retrospective cohort study evaluated adult patients who were admitted within a 7-hospital health system and received SPS or SZC for a serum potassium level greater than 5.0 mEq/L. Patients receiving dialysis prior to SPS/SZC administration, those receiving other potassium-lowering medications within 6 hours prior to blood sampling for a repeat potassium level, and those started on kidney replacement therapy prior to sampling for a repeat potassium level were excluded.
Results: Following evaluation of 3,903 patients, the mean reduction in serum potassium 4 to 24 hours after binder administration was 0.96 mEq/L with SPS and 0.78 mEq/L with SZC (P < 0.0001). The median dose of SPS was 30 g (interquartile range [IQR], 15-30 g) while the median (IQR) dose of SZC was 10 g (10-10 g). Resolution of hyperkalemia within 24 hours was achieved in a higher percentage of patients with use of SPS (74.9%) versus SZC (68.8%) (P < 0.001).
Conclusion: One of the largest comparisons of SPS and SZC conducted to date, this study demonstrated the effectiveness and safety of both agents. While a statistically greater reduction in serum potassium was observed with use of SPS, there was significant dosing variability among agents that limited the ability to directly compare specific doses. Further investigation is needed to determine the optimal dose of each agent for acute hyperkalemia management. This data will inform clinical decisions about the choice of potassium binder for acute hyperkalemia.
Keywords: cation exchange resins; hyperkalemia; potassium binder; sodium polystyrene sulfonate; sodium zirconium cyclosilicate.
© American Society of Health-System Pharmacists 2023. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
-
Single Dose of Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate in Hospitalized Patients With Hyperkalemia.Ann Pharmacother. 2023 Sep;57(9):1044-1052. doi: 10.1177/10600280221141918. Epub 2023 Jan 13. Ann Pharmacother. 2023. PMID: 36637028
-
Sodium polystyrene sulfonate versus sodium zirconium cyclosilicate for the treatment of hyperkalemia in the emergency department.Am J Emerg Med. 2023 Mar;65:59-64. doi: 10.1016/j.ajem.2022.12.043. Epub 2022 Dec 27. Am J Emerg Med. 2023. PMID: 36586223
-
Comparison of Sodium Zirconium Cyclosilicate to Sodium Polystyrene Sulfonate in the Inpatient Management of Acute Hyperkalemia.J Pharm Pract. 2024 Jun;37(3):728-735. doi: 10.1177/08971900231176462. Epub 2023 May 30. J Pharm Pract. 2024. PMID: 37254518
-
Effects and Safety of a Novel Oral Potassium-Lowering Drug-Sodium Zirconium Cyclosilicate for the Treatment of Hyperkalemia: a Systematic Review and Meta-Analysis.Cardiovasc Drugs Ther. 2021 Oct;35(5):1057-1066. doi: 10.1007/s10557-020-07134-2. Epub 2021 Jan 18. Cardiovasc Drugs Ther. 2021. PMID: 33459923 Free PMC article.
-
An evaluation of sodium zirconium cyclosilicate as a treatment option for hyperkalemia.Expert Opin Pharmacother. 2021 Jan;22(1):19-28. doi: 10.1080/14656566.2020.1810234. Epub 2020 Sep 7. Expert Opin Pharmacother. 2021. PMID: 32892634 Review.
Cited by
-
Evaluation of Monotherapy Sodium Zirconium Cyclosilicate Versus Sodium Polystyrene Sulfonate for Acute Hyperkalemia: A Cohort Study.Hosp Pharm. 2024 Oct 11:00185787241287676. doi: 10.1177/00185787241287676. Online ahead of print. Hosp Pharm. 2024. PMID: 39544819 Free PMC article.
-
Comparison of Three Potassium Binders in Patients With Acute Hyperkalemia.Cureus. 2025 Jun 28;17(6):e86922. doi: 10.7759/cureus.86922. eCollection 2025 Jun. Cureus. 2025. PMID: 40726889 Free PMC article.
-
Sodium zirconium cyclosilicate versus sodium polystyrene sulfonate for treatment of hyperkalemia in hemodialysis patients: a randomized clinical trial.BMC Nephrol. 2025 May 6;26(1):227. doi: 10.1186/s12882-025-04129-9. BMC Nephrol. 2025. PMID: 40329202 Free PMC article. Clinical Trial.
-
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023. J Pharm Pharm Sci. 2023. PMID: 38173862 Free PMC article.
-
Disorders of potassium homeostasis after kidney transplantation.World J Transplant. 2024 Sep 18;14(3):95905. doi: 10.5500/wjt.v14.i3.95905. World J Transplant. 2024. PMID: 39295980 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources